PsiThera Closes $25 Million Financing

AbbVie Ventures and Lumination Capital join existing investors Samsara BioCapital and Lightstone Ventures in the round.

Updated on Nov. 10, 2026 in Tech

Isometric editorial illustration of a single unlabeled oral tablet on a matte laboratory bench in front of stacked research-facility blocks, in muted slate, cream, and oxblood.
PsiThera closed a $25 million financing led by new investors AbbVie Ventures and Lumination Capital alongside existing backers Samsara BioCapital and Lightstone Ventures. AI Illustration. Upload story photo >

PsiThera, a biotechnology company headquartered in Watertown, Massachusetts, closed a $25 million financing. AbbVie Ventures and Lumination Capital are new investors, while Samsara BioCapital and Lightstone Ventures are existing lead investors.

Why it matters

The financing supports PsiThera's push to develop oral inhibitors for immune-mediated disease, an area where injectable anti-TNFα biologics are already approved across a broad range of conditions. The company's QUAISAR platform, which combines physics-based molecular simulation, machine learning, and experimental biophysics, is central to that effort.

QUAISAR models protein motion to identify transient binding pockets that conventional structure-based design cannot see, and the lead TNFα program moved from hit identification to lead optimization in four months. The extraction does not indicate how the platform's predictive accuracy has been validated against clinical outcomes.

The players

PsiThera

PsiThera is a Watertown, Massachusetts biotechnology company developing oral inhibitors of immune-mediated cytokine pathways using its QUAISAR platform.

AbbVie Ventures

AbbVie Ventures is the venture investment arm of the pharmaceutical company AbbVie, which markets injectable anti-TNFα therapies.

Lightstone Ventures

Lightstone Ventures is a venture capital firm and an existing lead investor in PsiThera's financing.

The details

Proceeds from the $25 million financing are expected to fund operations, nomination of a development candidate for the lead oral TNFα inhibitor, and initiation of IND-enabling studies, as well as advancement of the oral TL1A program into lead optimization. PsiThera's initial programs target the TNFα, TL1A, and IL-6 cytokine pathways.

Timeline

  1. November 10, 2026: PsiThera announced the closing of its $25 million financing.

Roadmap

PsiThera's oral TNFα inhibitors are designed to improve the therapeutic index relative to injectable anti-TNFα biologics, which are already approved across a broad range of immune-mediated diseases. The effort marks a push to bring a delivery format change to a drug class that has so far been dominated by injections.

For patients living with immune-mediated diseases, oral options would change how treatment is delivered if the programs reach the clinic. The extraction does not indicate a timeline for clinical availability, so near-term changes to care are not established by this financing.

The takeaway

A financing close is an early step, and the company's own milestones, including development candidate nomination and IND-enabling studies, will indicate whether the oral approach advances. Readers tracking immune-disease drug development can watch those stages as the clearest signals.

Further reading

For more on the sector, see the Biotech coverage on Wisevoter.

Source note: This article includes information reported by The Manila times.